Waltham, Massachusetts, 19 de janeiro de 2026 – A BVI, líder mundial no mercado de dispositivos oftálmicos, anunciou hoje a nomeação de Jim Hollingshead como Presidente e Diretor Executivo. Hollingshead sucede a Shervin Korangy, que continuará a ser consultor da BVI e vai iniciar novas funções como consultor sénior da TPG Capital.

Hollingshead tem uma experiência de mais de 20 anos na liderança e crescimento de empresas de dispositivos médicos e ciências da vida. Mais recentemente, foi Diretor Executivo da Insulet, um líder inovador na administração de insulina. Durante o mandato de Hollingshead, a Insulet reforçou a sua liderança no mercado através do alargamento da gama de produtos, incluindo o lançamento do primeiro sistema de administração automática de insulina com bomba adesiva do setor. Anteriormente, Hollingshead esteve 12 anos na ResMed, onde ocupou o cargo de Presidente da área de Cuidados Respiratórios e do Sono da empresa.

“Desde sempre me inspirou o papel que a inovação tecnológica pode desempenhar na melhoria da experiência e dos resultados dos doentes”, afirmou Hollingshead. “A BVI está a transformar os cuidados oftalmológicos através de uma missão simples e eficaz de fornecer soluções inovadoras e de confiança, adaptadas às necessidades específicas dos médicos e dos seus doentes. É um privilégio integrar a equipa da BVI, à medida que aproveitamos o já forte dinamismo da empresa e lançamos várias plataformas novas e líderes no setor.”

Ao longo dos últimos anos, a BVI manteve o seu dinamismo e expandiu significativamente o seu portefólio dedicado. A empresa desenvolveu uma das linhas de produtos mais robustas do setor e oferece agora uma solução processual completa para o mercado da cirurgia da catarata e da retina. A empresa expandiu a sua plataforma de lentes intraoculares (IOL) para atender ao aumento da procura global e introduziu novas linhas de produtos, como a SERENITY e a SERENITY Toric, que proporcionam uma visão de longo e médio alcance. Em 2025, a BVI recebeu a aprovação da FDA para as suas IOL trifocais FINEVISION HP, o que resultou na sua posição de liderança global em IOLs premium para doentes dos EUA. A empresa também estreou o seu sistema de glaucoma Leos™, aprovado pela FDA, o que marcou um avanço significativo no tratamento do glaucoma e revelou o Virtuoso®, uma nova plataforma de faco-vitrectomia de dupla função para procedimentos de catarata e vítreo-retinianos.

“A visão estratégica, o discernimento e o historial de inovação e transformação de Jim no setor dos dispositivos médicos fazem dele uma excelente opção para a BVI, uma vez que a empresa continua a avançar na sua liderança de mercado e a aumentar o seu impacto a nível mundial”, afirmou Ron Labrum, Presidente da BVI. “Queremos reconhecer a liderança de Shervin enquanto a BVI desenvolvia um dos portefólios de produtos mais inovadores do setor e sabemos que a equipa continuará a beneficiar da sua experiência.”

“Quero agradecer a toda a equipa da BVI pela sua parceria a transformar a empresa na plataforma dinâmica que é hoje”, disse Korangy. “Estou orgulhoso da amplitude da nossa carteira e da gama de produtos que construímos, criando um desafio ao status quo de longa data do setor. Espero poder continuar a apoiar a empresa na consolidação do seu percurso sob a liderança do Jim.”

Acerca da BVI
A BVI® é uma empresa global diversificada de dispositivos oftálmicos cuja missão é fornecer soluções de alta qualidade e inovação para o avanço da cirurgia ocular e a melhoria da visão dos doentes. Com nove décadas de desenvolvimento de produtos e soluções líderes de mercado, a BVI forma parcerias com cirurgiões oftalmológicos para melhorar a visão de milhões de doentes em todo o mundo. A nossa empresa apoia equipas cirúrgicas em mais de 90 países de todo o mundo, quer diretamente, quer através da nossa rede de distribuidores de confiança.

Para mais informações sobre a BVI e a sua missão de promover o futuro da visão, visite bvimedical.com

---

Contacto para a imprensa

• BVI announces Virtuoso®, its first dual-function phaco-vitrectomy system designed to deliver advanced control, efficiency, and versatility for both cataract and vitreoretinal surgery.
• European debut planned for 2025 Global ophthalmic congresses in Europe (Euretina and ESCRS).  

Waltham, Mass., September 3, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the European market unveiling of its innovative phaco-vitrectomy surgical platform, Virtuoso®, a dual-function system designed for both cataract and vitreoretinal procedures.

Virtuoso® is engineered to redefine control and accuracy in ophthalmic surgery by combining advanced technologies across fluidics control, vitreoretinal applications, ultrasound delivery, and usability into a single, high-performance platform with a thoughtful footprint design to optimize space in the operating room. Its introduction in the ophthalmic community marks a significant milestone in BVI’s mission to reshape the future of ophthalmic care with best-in-class solutions.

“Virtuoso® represents a significant leap in surgical technology, bringing efficiency and control to both anterior and posterior segment procedures,” said Shervin Korangy, President and CEO of BVI. “With Virtuoso®, we are expanding our presence in the equipment segment of ophthalmology and look forward to watching millions of patients benefit from this technology. The excitement from the ophthalmic community for this much anticipated introduction is palpable.”

Built for the Future of Eye Surgery
Virtuoso® is designed to deliver market-leading applications across cataract, vitrectomy, and combined procedures, built into One Platform — providing versatility in multi-specialty centers and high-efficiency surgical environments.

Virtuoso® is positioned at the top tier of ophthalmic surgical systems, addressing the needs of a growing number of ambulatory surgical centers and hospitals seeking flexible, cost-effective platforms. The system also strengthens BVI’s value proposition by coupling with its extensive portfolio of consumables and IOLs.

Leading surgeons have already highlighted the system’s breakthrough features, coming from their testing. Dr. Tommaso Rossi (Italy) noted: “Virtuoso has a very novel fluidics concept maintaining target IOP throughout ALL procedure steps, from phaco to I/A, uniquely fusing the control of a flow pump with the efficiency of a pressure pump. Also, the featured Load Sensing Phaco maintains the programmed U/S energy regardless of lens resistance—this may translate into enhanced energy delivery.”

In the field of vitreoretinal surgery, Dr. David Steel (UK) emphasized the platform’s advanced capabilities: “The new Virtuoso platform shows very promising capabilities for vitreoretinal surgery: an enhanced aspiration performance matched with infusion under a variety of challenging scenarios, paired with high-speed and dual-action cutting performance, even under load with a bent shaft.”

BVI is planning to introduce the Virtuoso® phaco-vitrectomy system at the upcoming 2025 Global surgical ophthalmic congresses in Europe (ESCRS, Euretina) through targeted promotional activities. These congresses will also feature the first-ever Virtuoso® abstracts included in the Scientific Program: these will cover data about post-occlusion break surge, energy delivery consistency, vitrectomy probe stiffness and aspiration efficiency.

As evidence of a strong responsibility towards the ophthalmic community, BVI has committed to a prospective, single-center, clinical investigation at LMU Klinikum, Munich, Germany, under the lead of Prof. Priglinger, with the aim of confirming the safety and effectiveness of Virtuoso® phaco-vitrectomy system.

Commercial availability will begin in selected European markets, with a global rollout according to appropriate market approvals.

*** 

About BVI 

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients’ vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors. 

To learn more about BVI and its mission to advance the future of vision, visit https://www.bvimedical.com 

Press Contact 

David Chavez 
Global Communications Lead 
[email protected] 
+1 (857) 869 8706

• BVI received four awards in the 2025 Medical Device Network Excellence Awards—for Innovation, Product Launches, R&D, and Investments—recognizing its leadership in advancing ophthalmic technology and global growth.
• Key achievements include the launch of SERENITY IOLs with ISOFOCAL technology, FDA clearance of the Leos™ glaucoma system, and a $1 billion capital raise supporting strategic expansion and continued innovation.

WALTHAM, Mass., July 9th, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, has been recognized with four prestigious accolades in the 2025 Medical Device Network Excellence Awards. The company earned top honors in Innovation, Research and Development, Investments, and Product Launches, underscoring its leadership in advancing eye care technology, strategic growth, and breakthrough product development.

The Excellence Awards celebrate the most impactful achievements and innovations across the medical device industry. Powered by Global Data’s proprietary business intelligence, the program highlights the companies and individuals driving meaningful changes across twelve key categories including Innovation, Product Launches, R&D, Safety, and Marketing.

“Being recognized across four distinct categories is an extraordinary honor and a reflection of the energy and purpose that drive our teams every day,” said Shervin Korangy, President & Chief Executive Officer at BVI. “These awards validate our vision to lead the ophthalmic industry not only through cutting-edge technologies, but also through bold financial strategy and meaningful global expansion. We’re excited by the impact we’re making — and even more inspired by what’s ahead.”

BVI was recognized in the following categories:

• Breakthrough Innovation in Ophthalmic Implants: For its patented ISOFOCAL technology, featured in the newly launched SERENITY and SERENITY Toric premium monofocal IOLs.
• Award-Winning Product Launch: SERENITY IOL Portfolio: For introducing the SERENITY IOL series, representing the second generation of BVI’s ISOPURE family.
• R&D Leadership in Minimally Invasive Glaucoma Technology: For the Leos™ Laser Endoscopy Ophthalmic System, a groundbreaking platform that combines laser treatment with endoscopic visualization. Leos has received FDA 510(k) clearance and is planned for commercial launch in late 2025.
• Strategic Capital Investment and Global Expansion: Following the successful $1 billion capital raise in partnership with TPG, enabling manufacturing expansion, global footprint growth, and accelerated product innovation.

“Winning in both the Innovation and Product Launch categories is a powerful acknowledgment of the incredible work our teams have done to bring the SERENITY IOL portfolio to market,” said Andrew Chang, Chief Commercial Officer at BVI. “We’re proud to set a new standard in monofocal IOLs and excited for what lies ahead. With upcoming launches on the horizon, we remain deeply committed to shaping the future of ophthalmology.”

These four awards reflect the strength of BVI’s strategy, the depth of its innovation, and the dedication of its global teams. As the company continues to expand its portfolio, invest in next-generation technologies, and scale global operations, BVI is well-positioned to shape the future of ophthalmology and deliver lasting value to patients, surgeons, and partners around the world.

About BVI

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients’ vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

To learn more about BVI and its mission to advance the future of vision, visit https://www.bvimedical.com

---

Press Contact
David Chavez
Global Communications Lead
[email protected]
+1 (857) 869 8706

• Positions company for several new product launches and scaling of operations to meet rising demand globally
• $1 billion of new capital raised to refinance debt and fund accelerated growth

Waltham, MA, March 10, 2025 – BVI Medical, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the completion of a $1 billion strategic capital raise in partnership with TPG, a leading global alternative asset management firm. This investment, which fully refinances BVI’s existing debt and adds new equity from both TPG and new investors, strengthens the company’s financial position as it looks to accelerate product innovation and expand its global footprint.

This financing follows a period of accelerated momentum for BVI, during which the company has significantly grown its portfolio of product offerings and built one of the most robust product pipelines in the industry. Most recently, BVI expanded its IOL manufacturing in Europe to meet growing global demand, introduced new product lines such as SERENITY and SERENITY Toric premium monofocal IOLs, and strengthened its market position through strategic acquisitions.

“This investment marks a pivotal moment for BVI as we scale our capabilities to meet the rising demand for advanced ophthalmic solutions,” said Shervin Korangy, President and CEO. “We are redefining the future of eye surgery and changing the competitive landscape by driving the launch of breakthrough technologies that will empower surgeons worldwide.”

“TPG is proud to continue our partnership with BVI as it works to scale its global impact in ophthalmic care,” said Kendall Garrison, Partner at TPG. “The company has strengthened its market position while advancing patient care worldwide and this investment will further drive innovation and expansion. We look forward to supporting BVI’s continued success,” added John Schilling, MD, Co-Managing Partner at TPG Capital.

***

About BVI Medical

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients’ vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

To learn more about BVI Medical and its mission to advance the future of vision, visit https://www.bvimedical.com.

Press Contact

David Chavez

Global Communications Lead

[email protected]

+1 (857) 869 8706